
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma's financial position exhibits strength, with cash, cash equivalents, and marketable securities increasing to $320 million, bolstered by a recent private placement, despite modest increases in operating expenses. The company is experiencing optimistic developments in its clinical pipeline, particularly highlighted by the potential of LYL273, which shows promise in achieving durable complete responses in challenging patient populations. Additionally, expert feedback has reinforced the company's competitive edge in the CAR-T market, indicating significant opportunities for growth and an increased probability of regulatory approval for its therapies.
Bears say
The financial outlook for Lyell Immunopharma appears negative primarily due to significant risks associated with its product pipeline and overall market growth potential. A decrease in research and development expenditures from $34.9 million in 2Q25 to $28.2 million in 3Q25 indicates potential operational challenges or reduced commitment to advancing critical clinical trials. Furthermore, concerns surrounding the durability of efficacy and safety management for its assets, specifically LYL273, hinder investor confidence, particularly as current data does not provide sufficient evidence to substantiate the therapy's effectiveness in the competitive landscape of CAR-T treatments.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares